Cefotaxime Sodium Powder Shortage: FDA Status Update
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA lists Cefotaxime Sodium Powder, for Solution as currently in shortage status, but it is available from the listed manufacturer.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on May 6, 2026 and geographically references United States. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Cefotaxime Sodium Powder, for Solution.
Cefotaxime Sodium Powder Shortage
As a professional health news writer for Areazine, I am reporting on the current status of Cefotaxime Sodium Powder, for Solution, which may affect patients relying on this medication. We aim to provide clear, factual information to help you navigate this situation.
What's in Shortage
The drug in shortage is Cefotaxime Sodium Powder, for Solution (generic name). Brand names include CEFOTAXIME. The dosage form is Powder, for Solution. The current status is listed as Current by the FDA, with the shortage first posted on 02/17/2015 and last updated on 04/30/2026. This medication falls under the therapeutic categories of Anti-Infective and Pediatric.
Which Manufacturers Are Affected
The affected manufacturer is SteriMax, Inc. For the presentation Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02), it is available. For the presentation Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02), it is also available. Contact information for SteriMax, Inc. is 800-881-3550.
Why There's a Shortage
No specific reason for the shortage was provided in the source data.
What Patients Should Do
If you are affected by this situation, we recommend talking to your pharmacist to check the latest availability. You may also contact the manufacturer directly using the provided information. Remember to ask your healthcare provider for guidance on your specific needs. Please note that this article does not provide medical advice, and patients should always consult their healthcare provider before making any changes to their medication.
Source
This information is sourced from the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,684 characters here).
Similar severity timing
Same severity (low) notices issued closest in time to May 6, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.